Tina Deng, MSc, a principal medical devices analyst at GlobalData commented: “There is growing evidence that diabetic ketoacidosis rates can be largely reduced by using improved CGM devices. As these devices advance, implementing smarter features that track a wider variety of data, more healthcare providers and patients are using CGM to improve glycemic control and potentially increase patient self-management—which is especially pertinent during the COVID-19 crisis.”
The CGM devices market grew robustly in the third quarter. Abbott’s FreeStyle Libre series reported a strong growth of 37.9 percent in the quarter (ended Sept. 30), driven by its new generation, FreeStyle Libre 2 launching in Q3. The device can be used for adults and children ages four and up with improved accuracy and performance standards at the same cost of the original FreeStyle Libre. Although facing intense competition from Abbott, DexCom also reported Q3 revenue growth of 26 percent when compared with Q3 2019.
Deng concluded: “In the U.S., Medicare and other payers are now covering CGM for the Type 2 intensive population. This favorable reimbursement policy will only accelerate the CGM market growth further. In addition, major players are working on extending the CGM usage from Type 1 diabetes and Type 2 diabetes on intensive insulin therapy to broader population including non-intensive Type 2 diabetes, pre-diabetes, pregnancy, and the hospital market.”